Patent application number | Description | Published |
20090148384 | FUNCTIONALIZED, SOLID POLYMER NANOPARTICLES COMPRISING EPOTHILONES - The present invention describes polymer nanoparticles with a cationic surface potential, in which both hydrophobic and hydrophilic pharmaceutically active substances can be encapsulated. The hydrophilic and thus water-soluble substances are encapsulated in the particle core by co-precipitation through ionic complexing with a charged polymer. Both therapeutic agents and diagnostic agents can be used as pharmaceutically active substances for encapsulation. The cationic particle surface permits stable, electrostatic surface modification with partially oppositely charged compounds, which can contain target-specific ligands for improving passive and active targeting. | 06-11-2009 |
20100196280 | FUNCTIONALIZED SOLID POLYMER NANOPARTICLES FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS - The present invention describes polymer nanoparticles with a cationic surface potential, in which both hydrophobic and hydrophilic pharmaceutically active substances can be encapsulated. The hydrophilic and thus water-soluble substances are encapsulated in the particle core by co-precipitation through ionic complexing with a charged polymer. Both therapeutic agents and diagnostic agents can be used as pharmaceutically active substances for encapsulation. The cationic particle surface permits stable, electrostatic surface modification with partially oppositely charged compounds, which can contain target-specific ligands for improving passive and active targeting. | 08-05-2010 |
20110052699 | DRUG DELIVERY SYSTEM WITH STABILISING EFFECT - A drug delivery system also intended as unit dosage form comprising a thin water-soluble film matrix, wherein said film matrix comprises
| 03-03-2011 |
20110097405 | ESTRADIOL-CONTAINING DRUG DELIVERY SYSTEM - The present invention relates to drug delivery systems in the form of thin water-soluble films (wafers), which contain estradiol, or derivatives thereof, in low amounts. The wafers of the present invention are suitable for treating, alleviating or preventing a physical condition in a female mammal caused by insufficient endogenous levels of estrogen. | 04-28-2011 |
20110293720 | PROGESTIN-CONTAINING DRUG DELIVERY SYSTEM - The present invention relates to drug delivery compositions in the form of thin water-soluble films (wafers), which contain small particles that comprise at least one progestin and at least one protective agent. The protective agent provides effective taste-masking of the progestin due to limited release of the progestin in the mouth. The progestin is hence not absorbed via the buccal route, but rather via the enteral (per-oral) route. | 12-01-2011 |
20120064166 | FORMULATION COMPRISING DROSPIRENONE FOR SUBCUTANEOUS OR INTRAMUSCULAR ADMINISTRATION - The present invention relates to a composition comprising Drospirenone dispersed in a liquid or semi-solid lipophilic vehicle. The present invention further relates to the use of such compositions as contraceptives and for treatment of diseases, disorders and symptoms associated with deficient endogenous levels of estrogen in women. | 03-15-2012 |
20120114757 | PARTICLES COMPRISING DROSPIRENONE ENCAPSULATED IN A POLYMER - The present invention relates to particles comprising Drospirenone encapsulated in a polymer selected from the group consisting of glycolic acid polymer, lactic acid polymer, poly caprolactones, poly anhydrides and any copolymer of these, e.g., poly(lactic acid-co-glycolic acid) polymer and any combination of these. Furthermore, the present invention also relates to compositions comprising such particles. The present invention also relates to the use of such particles or compositions as contraceptives and for treatment of diseases, disorders and symptoms associated with deficient endogenous levels of estrogen in women. | 05-10-2012 |
20120172343 | PHARMACEUTICAL COMPOSITION FOR EMERGENCY CONTRACEPTION - The invention relates to pharmaceutical compositions for emergency contraception, to the use of levonorgestrel in combination with COX inhibitors for the preparation of pharmaceutical compositions for the stated purpose, and to a method for preparing these pharmaceutical compositions. | 07-05-2012 |
20120189599 | MEDICATION FOR ORAL ADMINISTRATION, COMPRISING AT LEAST ONE ESTROGEN AND/OR AT LEAST ONE GESTAGEN AND AT LEAST ONE PROBIOTIC BACTERIAL STRAIN - The present invention relates to a medicament for oral administration containing at least one estrogen and/or one gestagen and at least one probiotic bacterial strain, such as for example | 07-26-2012 |
20120207836 | DRUG DELIVERY SYSTEMS (WAFER) FOR PEDIATRIC USE - The present invention describes drug delivery compositions in the form of thin water-soluble films (wafers), which contain particles that comprise at least one active ingredient—which is not an estrogen and/or a progestin and/or an alkaline earth metal salt of 5-methyl-(6S)-tetrahydrofolate—and at least one protective agent. The protective agent provides effective taste-masking of the active ingredient due to limited release of the active ingredient in the mouth. The active ingredient is hence not absorbed via the buccal route, but rather via the enteral (per-oral) route. The particles contained in the wafer provided by the present invention have a particle size of below 40 μm thereby resulting in an acceptable sensation in the mouth while dissolving. Such wafers are especially suitable for pediatric use. | 08-16-2012 |
20120263762 | STABILISED PARTICLES COMPRISING 5-METHYL-(6S)-TETRAHYDROFOLATE - The present invention relates to small stabilised particles comprising a crystalline form of an alkaline earth metal salt of 5-methyl-(6S)-tetrahydrofolate and at least one protective agent. Such particles confer stability to the alkaline earth metal salt of 5-methyl-(6S)-tetrahydrofolate, and is conveniently incorporated in unit dosage forms, such as wafers. | 10-18-2012 |
20120282340 | DRUG DELIVERY SYSTEM - The present invention relates to drug delivery systems in the form of thin water-soluble films (wafers), which contain an Estrogen Receptor beta (ER-β) selective agonist. The wafers of the present invention are suitable for treating, alleviating or preventing a physical condition in a female mammal caused by insufficient endogenous levels of estrogen. | 11-08-2012 |